Expression of Molecular Markers in the Tumor and Survival Prognosis in Osteosarcoma

被引:33
作者
Boulytcheva, I. V. [1 ]
Soloviev, Yu. N. [2 ]
Kushlinskii, N. E. [2 ]
Mahson, A. N. [1 ]
机构
[1] Moscow Oncol Hosp 62, Dept Pathol Anat, Moscow, Russia
[2] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia
关键词
osteosarcoma; expression; p53; VEGF; Flt-1/VEGFR1; Ab-1; EGFR; HER-2/neu; ENDOTHELIAL GROWTH-FACTOR; POOR-PROGNOSIS; HER-2/NEU; BCL-2; P53;
D O I
10.1007/s10517-010-1114-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Immunohistochemical study of p53, VEGF, Flt-1/VEGFR1 Ab-1, EGFR, HER-2/neu, Bax, and Cox-2 expression in osteosarcomas was carried out in 40 patients aged 16-70 years. Expression of p53 was detected in 27.5% tumors, VEGF in 15%, Flt-1/VEGFR1 Ab-1 in 97.5%, EGFR in 52.5%, HER-2/neu in 32.5%, Bax in 77.8%, and Cox-2 in 32.3% tumors. Multifactorial analysis showed that the expression of HER-2/neu (p=0.004), p53 (p=0.01), and Cox-2 (p=0.04) in osteosarcomas significantly correlated with unfavorable prognosis for overall survival, while HER-2/neu (p=0.02) and Cox-2 (p=0.003) with relapse-free survival. Analysis of HER-2/neu, p53, and Cox-2 expression in the primary tumor should be taken into consideration in the treatment of patients with osteosarcoma.
引用
收藏
页码:237 / 242
页数:6
相关论文
共 16 条
[1]  
[Абелев Г.И. Abelev G.I.], 2008, [Биохимия, BIOCHEMISTRY (MOSCOW), Biokhimiya], V73, P605
[2]   VEGF Expression as a Prognostic Marker in Osteosarcoma [J].
Bajpai, Jyoti ;
Sharma, Meharchand ;
Sreenivas, Vishnubhatla ;
Kumar, Rakesh ;
Gamnagatti, Shivanand ;
Khan, Shah Alam ;
Rastogi, Shishir ;
Malholtra, Arun ;
Bakhshi, Sameer .
PEDIATRIC BLOOD & CANCER, 2009, 53 (06) :1035-1039
[3]   Her-2/neu, P-53, and Their Coexpression in Osteosarcoma [J].
Bakhshi, Sameer ;
Gupta, Ajay ;
Sharma, Meher C. ;
Khan, Shah Alam ;
Rastogi, Shishir .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2009, 31 (04) :245-251
[4]  
FRANK GA, 2009, PRECISE DIAGNOSIS CA
[5]  
Imyanitov E.N, 2007, MOL ONCOLOGY CLIN AS
[6]   Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma [J].
Kaseta, Maria-Kyriaki A. ;
Khaldi, Lubna ;
Gomatos, Ilias P. ;
Tzagarakis, George P. ;
Alevizos, Leonidas ;
Leandros, Emmanuel ;
Papagelopoulos, Panayiotis J. ;
Soucacos, Panayiotis N. .
JOURNAL OF SURGICAL ONCOLOGY, 2008, 97 (03) :259-266
[7]   The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma [J].
Kaya, M. ;
Wada, T. ;
Nagoya, S. ;
Sasaki, M. ;
Matsumura, T. ;
Yamashita, T. .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2009, 91B (06) :784-788
[8]   Expression of cyclooxygenase-2 in osteosarcoma of bone [J].
Masi, Laura ;
Recenti, Raffaella ;
Silvestri, Sandra ;
Pinzani, Pamela ;
Pepi, Monica ;
Paglierani, Milena ;
Brandi, Maria Luisa ;
Franchi, Alessandro .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2007, 15 (01) :70-76
[9]   Livin and Bcl-2 expression in high-grade osteosarcoma [J].
Nedelcu, T. ;
Kubista, B. ;
Koller, A. ;
Sulzbacher, I. ;
Mosberger, I. ;
Arrich, F. ;
Trieb, K. ;
Kotz, R. ;
Toma, C. D. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (02) :237-244
[10]  
Onda M, 1996, CANCER-AM CANCER SOC, V77, P71, DOI 10.1002/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.0.CO